LOS ANGELES, Nov 29 (Reuters) - Johnson & Johnson (JNJ.N: Quote, Profile, Research) said on Thursday its fourth-quarter results would include a special after-tax, noncash charge of $440 million from a write-down related to a decline in sales of acute heart failure drug Natrecor.
